Pistacia vera L. oleoresin and levofloxacin is a synergistic combination against resistant Helicobacter pylori strains.
Anti-Bacterial Agents
/ pharmacology
Anti-Infective Agents
/ pharmacology
Biofilms
/ drug effects
Drug Resistance, Bacterial
/ drug effects
Drug Synergism
Helicobacter Infections
/ drug therapy
Helicobacter pylori
/ drug effects
Humans
Levofloxacin
/ pharmacology
Microbial Sensitivity Tests
Pistacia
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
30
08
2018
accepted:
19
02
2019
entrez:
16
3
2019
pubmed:
16
3
2019
medline:
2
10
2020
Statut:
epublish
Résumé
The increasing multidrug resistance in Helicobacter pylori, also correlated to its biofilm-forming ability, underlines the need to search novel strategies to improve the eradication rate. Natural compounds are proposed as antibiotic-resistant-breakers capable to restore the efficacy of conventional drugs. Aim of this work was to evaluate the capability of Pistacia vera L. oleoresin (ORS) to synergize with levofloxacin (LVX) against resistant H. pylori strains. The antimicrobial activity of P. vera L. ORS and LVX and their combinations was determined by MIC/MBC (in neutral and acidic environments) and checkerboard tests. The anti-biofilm effect was determined by biomass quantification. In vivo Galleria mellonella model was used to confirm in vitro data. Pistacia vera L. ORS and LVX MICs ranged respectively from 780 to 3120 mg/l and from 0.12 to 2.00 mg/l, at pH 7.0 and 5.5. MBCs were similar to MICs. Pistacia vera L. ORS was able to synergize with LVX, restoring its effectiveness in LVX resistant strains. Pistacia vera L. ORS, LVX and their synergistic combinations displayed significant biofilm reduction. Pistacia vera L. ORS and LVX, showed protective effect against H. pylori infection on G. mellonella (62% and 63% of survival, respectively). Pistacia vera L. ORS can be considered a promising potentiator to restore the effectiveness of LVX tackling the H. pylori antibiotic resistance phenomenon.
Identifiants
pubmed: 30874618
doi: 10.1038/s41598-019-40991-y
pii: 10.1038/s41598-019-40991-y
pmc: PMC6420558
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Levofloxacin
6GNT3Y5LMF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4646Références
Przegl Epidemiol. 2018;72(1):57-73
pubmed: 29667381
Phytother Res. 2018 Mar;32(3):488-495
pubmed: 29193368
Phytomedicine. 2010 Mar;17(3-4):296-9
pubmed: 19879118
Biomed Chromatogr. 2005 May;19(4):285-311
pubmed: 15651084
Environ Health Prev Med. 2017 Aug 02;22(1):63
pubmed: 29165147
BMC Microbiol. 2014 Aug 27;14:228
pubmed: 25170542
FEMS Microbiol Lett. 2016 Apr;363(8):
pubmed: 27036144
World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):171-8
pubmed: 27158532
Phytomedicine. 2008 Aug;15(8):639-52
pubmed: 18599280
Phytomedicine. 2009 Mar;16(2-3):97-110
pubmed: 19211237
Phytother Res. 2005 Mar;19(3):198-202
pubmed: 15934015
Arch Oral Biol. 2018 Dec;96:208-215
pubmed: 30296655
Int J Immunopathol Pharmacol. 2015 Dec;28(4):595-602
pubmed: 26526205
J Res Pharm Pract. 2016 Oct-Dec;5(4):248-251
pubmed: 27843960
ScientificWorldJournal. 2013 Dec 15;2013:219815
pubmed: 24453812
Pharmaceuticals (Basel). 2009 Apr 01;2(1):2-10
pubmed: 27713219
FEBS Lett. 2011 Jun 6;585(11):1682-90
pubmed: 21549704
Indian J Med Microbiol. 2015 Oct-Dec;33(4):560-4
pubmed: 26470964
J Gastrointestin Liver Dis. 2010 Dec;19(4):409-14
pubmed: 21188333
J Chemother. 2001 Dec;13(6):611-4
pubmed: 11806621
World J Gastroenterol. 2014 May 21;20(19):5575-82
pubmed: 24914317
Clin Gastroenterol Hepatol. 2009 Feb;7(2):145-8
pubmed: 19026766
Phytomedicine. 2010 Nov;17(13):1061-6
pubmed: 20727725
Saudi J Biol Sci. 2019 Nov;26(7):1848-1855
pubmed: 31762667
J Antimicrob Chemother. 2003 Jul;52(1):1
pubmed: 12805255
Gut. 2013 Jan;62(1):34-42
pubmed: 22580412
Nat Rev Drug Discov. 2015 Dec;14(12):821-32
pubmed: 26493767
Scand J Gastroenterol. 2008;43(2):178-85
pubmed: 17918004
Pharm Biol. 2015 Jul;53(7):939-60
pubmed: 25430849
EXCLI J. 2015 Mar 30;14:496-503
pubmed: 26535038
Glob J Health Sci. 2011 Dec 29;4(1):149-61
pubmed: 22980106
Scand J Gastroenterol. 2016 Mar;51(3):263-9
pubmed: 26554617
Helicobacter. 2002 Oct;7(5):306-9
pubmed: 12390210
J Antimicrob Chemother. 2019 Apr 1;74(4):1069-1077
pubmed: 30668729
Biomed Chromatogr. 2005 Oct;19(8):586-605
pubmed: 15770609
Future Microbiol. 2018 May;13:671-687
pubmed: 29798689
Sci Rep. 2018 Feb 27;8(1):3701
pubmed: 29487357
Clin Microbiol Rev. 2007 Apr;20(2):280-322
pubmed: 17428887
Nat Prod Bioprospect. 2014 Aug;4(4):227-31
pubmed: 25089241
J Antimicrob Chemother. 2017 Nov 01;72(11):3085-3092
pubmed: 28961884
World J Gastroenterol. 2014 Feb 14;20(6):1450-69
pubmed: 24587621